Entry |
|
Name |
Irritable bowel syndrome |
Description |
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. It is characterized by symptoms of abdominal pain, bloating, and abnormal bowel movements, such as diarrhea or constipation. In IBS, there appears to be no organic substance or biochemical abnormality that can explain the symptoms. IBS can be classified into categories: constipation predominant IBS (IBS-C), diarrhea predominant IBS (IBS-D), mixed IBS (IBS-M), and un-subtyped IBS. Anticholinergic drugs, 5-HT3 receptor antagonist, high molecular weight polymers (polycarbophil calcium), gastrointestinal motility regulators, probiotics preparations, and laxatives are used in the treatment of IBS. However, they are not uniformly effective. Several studies of patients with IBS suggest that this disorder aggregates in families, and thus, appears potentially heritable. It has been reported that familial GUCY2C diarrhoea syndrome shares clinical characteristics with IBS-D.
|
Category |
Digestive system disease
|
Brite |
Human diseases [BR:br08402]
Digestive system diseases
Gastrointestinal diseases
H01615 Irritable bowel syndrome
Human diseases in ICD-11 classification [BR:br08403]
13 Diseases of the digestive system
Functional gastrointestinal disorders
DD91 Irritable bowel syndrome or certain specified functional bowel disorders
H01615 Irritable bowel syndrome
|
Gene |
|
Drug |
Dicyclomine hydrochloride [DR: D00717]
Alosetron hydrochloride [DR: D02829]
Hyoscyamine sulfate [DR: D00719]
Chlordiazepoxide hydrochloride and clidinium bromide [DR: D10247]
Lubiprostone [DR: D04790]
Linaclotide [DR: D09355]
Plecanatide [DR: D09948]
Tenapanor hydrochloride [DR: D11653]
Eluxadoline [DR: D10403]
|
Other DBs |
|
Reference |
|
Authors |
Saito YA |
Title |
The role of genetics in IBS. |
Journal |
|
Reference |
|
Authors |
Shah SL, Lacy BE |
Title |
Dietary Interventions and Irritable Bowel Syndrome: A Review of the Evidence. |
Journal |
|
Reference |
|
Authors |
von Volkmann HL, Nylund K, Tronstad RR, Hovdenak N, Hausken T, Fiskerstrand T, Gilja OH |
Title |
An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel. |
Journal |
|
Reference |
|
Authors |
Kobayashi S, Ikeda K, Suzuki M, Yamada T, Miyata K |
Title |
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. |
Journal |
|
Reference |
|
Authors |
Fukushima Y, Suzuki H, Matsuzaki J, Kiyosue A, Hibi T |
Title |
Efficacy of Solifenacin on Irritable Bowel Syndrome With Diarrhea: Open-label Prospective Pilot Trial. |
Journal |
|
LinkDB |
|